Does long term treatment with azathioprine predispose to malignancy and death in patients with systemic lupus erythematosus? (Nero P, Rahman A, Isenberg DA. Ann Rheum Dis 2004;63:325–6.)
We regret that the references for this letter were omitted. They are given below.
1
Hazleman B. Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens. Am J Med1985;78(suppl 1A):39–43.
2
Moll JMH. Drug therapy (3): “specific” drugs. In: Management of rheumatic disorders. 1st ed. London: Chapman and Hall: 1983:169–212.
3
Silman A, Petrie J, Hazleman B, Evans S. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20-year follow up study. Ann Rheum Dis1988;47:988–92.
4
Sutcliffe N, Smith C, Speight PM, Isenberg DA. Mucosa-associated lymphoid tissue lymphomas in two patients with rheumatoid arthritis on second-line agents, and secondary Sjögren syndrome. Rheumatology (Oxford)2000;39:185–8.